Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers

Article ID	Journal	Published Year	Pages	File Type
8536650	Pharmacological Research	2018	70 Pages	PDF

Keywords

PKC PDGFR VEGFR PI-3K CTT EGFR glial-cell derived neurotrophic factor CS or C-spine FGFR Artn GRL RS or R-spine GDNF K/E/D/D pKa shell residue 1 CDK GFRα Artemin transmembrane segment activation segment Kid catalytic loop kinase domain Targeted cancer therapy Gatekeeper regulatory spine catalytic spine NSCLC Non-small cell lung cancer Sh1 Phosphatidylinositol 3-kinase Men Multiple endocrine neoplasia neurturin Persephin protein kinase A Protein kinase C cyclin-dependent protein kinase kinase insert domain platelet-derived growth factor receptor vascular endothelial growth factor receptor Epidermal growth factor receptor fibroblast growth factor receptor

Related Topics

Health Sciences Pharmacology, Toxicology and Pharmaceutical Science Pharmacology

Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers

Authors

Robert Jr., Abdollah Sadeghi-Nejad,